“China Next: The Future Seen from the Greater Bay Area” has clinched the prestigious gold award in the TV category at the 44th Telly Awards, known as the “Oscars of the American TV industry”. Co-produced by the Discovery Channel, this compelling documentary features Lewis Lusuwi, a BGI Genomics automation engineer demonstrating how genetic testing technology advances precision medicine.
Credit: The Telly Awards
“China Next: The Future Seen from the Greater Bay Area” has clinched the prestigious gold award in the TV category at the 44th Telly Awards, known as the “Oscars of the American TV industry”. Co-produced by the Discovery Channel, this compelling documentary features Lewis Lusuwi, a BGI Genomics automation engineer demonstrating how genetic testing technology advances precision medicine.
Automation Engineer Chronicles Genetic Testing Applications
Lewis Lusuwi, from Zimbabwe, shares his unique perspective on how BGI Genomics uses the power of technology to help thalassemia patients via genetic testing. He recounts how his team launches a fully automated solution to reduce manual intervention, enhance accuracy, and improve efficiency in genetic testing procedures.
BGI Genomics α and β Thalassemia Gene Detection Kit’s Global Impact
There are approximately 345 million thalassemia gene carriers worldwide, with 30 million residing in China alone. Children with severe thalassemia do not undergo hematopoietic stem cell transplantation. They will need lifelong blood transfusion and iron removal treatment, which adds a heavy financial burden to the family. In light of this pressing issue, BGI Genomics has proactively sought innovative solutions, leveraging cutting-edge technology to advance genetic testing practices.
The company’s progressive efforts have significantly lowered the cost of thalassemia testing and benefited many across the world. By the end of 2022, BGI Genomics had provided free thalassemia gene testing to over 1.28 million individuals worldwide.
Bold Steps toward Precision Medicine
Lewis Lusuwi notes that with precision medicine, patients can receive tailored treatments that maximize efficacy and minimize adverse effects. The company fully supports the future of precision medicine, and the prevention and treatment of thalassemia is part of these efforts.
Adhering to the principle that “prevention is better than cure and must be accessible to all”, BGI Genomics remains steadfast in its commitment to public health. Leveraging the power of genetic technology, the company is dedicated to driving advancements that safeguard and enhance the health of communities worldwide.
– To learn more, please see full documentary on the Telly Awards website.
About BGI Genomics
BGI Genomics, headquartered in Shenzhen, China, is the world’s leading integrated solutions provider of precision medicine. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was listed on the Shenzhen Stock Exchange.
